NEOMARKERS RABBIT MONOCLONAL ANTI-HUMAN PROGESTERONE RECEPTOR ANTIBODY (CLONE SP2)

K060462 · Lab Vision Corp. · MXZ · Apr 24, 2006 · Hematology

Device Facts

• Record ID: K060462
• Device Name: NEOMARKERS RABBIT MONOCLONAL ANTI-HUMAN PROGESTERONE RECEPTOR ANTIBODY (CLONE SP2)
• Applicant: Lab Vision Corp.
• Product Code: MXZ · Hematology
• Decision Date: Apr 24, 2006
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.1860
• Device Class: Class 2

Indications for Use

Neomarkers Rabbit Monoclonal Anti-Human Progesterone Receptor Antibody (Clone SP2) is an immunohistochemical (IHC) assay intended for laboratory use for the qualitative detection of progesterone receptor (PR) antigen by light microscopy in sections of formalin fixed, paraffin embedded normal and neoplastic tissues on a Lab Vision automated slide stainer.

Device Story

Immunohistochemical assay; identifies progesterone receptor (PR) expression in formalin-fixed, paraffin-embedded breast tissue. Input: tissue sections on slides. Process: rabbit monoclonal antibody (Clone SP2) binds PR antigen in nuclear region; biotin-conjugated secondary antibody binds primary; avidin/streptavidin enzyme conjugate binds secondary; precipitating enzyme reaction product visualized via light microscopy. Used in clinical laboratories; operated by pathologists/technicians. Output: visual staining pattern on slide. Clinical use: pathologist evaluates staining intensity/distribution to determine PR status; aids in breast cancer therapy response assessment and prognosis.

Clinical Evidence

No clinical data provided in the summary document; device relies on analytical performance characteristics typical of IHC reagents.

Technological Characteristics

Rabbit monoclonal antibody (Clone SP2) for immunohistochemistry. Formulated for use on automated slide staining systems. Detects PR protein in formalin-fixed, paraffin-embedded tissue sections. Visualized via light microscopy.

Indications for Use

Indicated for qualitative detection of Progesterone Receptor (PR) in formalin-fixed, paraffin-embedded normal and neoplastic tissue sections. Used as an aid in assessing therapy response, prognosis, and management of breast cancer patients.

Regulatory Classification

Identification

Immunohistochemistry test systems (IHC's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. Their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. Similar devices intended for use with flow cytometry devices are not considered IHC's.

Special Controls

(2) Class II (special control, guidance document: “FDA Guidance for Submission of Immunohistochemistry Applications to the FDA,” Center for Devices and Radiologic Health, 1998). These IHC's are intended for the detection and/or measurement of certain target analytes in order to provide prognostic or predictive data that are not directly confirmed by routine histopathologic internal and external control specimens. These IHC's provide the pathologist with information that is ordinarily reported as independent diagnostic information to the ordering clinician, and the claims associated with these data are widely accepted and supported by valid scientific evidence. Examples of class II IHC's are those intended for semiquantitative measurement of an analyte, such as hormone receptors in breast cancer.

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
K060462

B. Purpose for Submission:
Marketing product in U.S.

C. Measurand:
Progesterone Receptor on formalin-fixed paraffin-embedded breast cancer specimens

D. Type of Test:
Immunohistochemical

E. Applicant:
Lab Vision Corporation

F. Proprietary and Established Names:
NeoMarkers Rabbit Monoclonal Anti-Human Progesterone Receptor Antibody (Clone SP2)

G. Regulatory Information:
1. Regulation section:
21 CFR §864.1860 Immunohistochemistry reagents and kits
2. Classification:
Class II
3. Product code:
MXZ

{1}

4. Panel:

Pathology 88

H. Intended Use:

1. Intended use(s):

Neomarkers Rabbit Monoclonal Anti-Human Progesterone Receptor Antibody (Clone SP2) is an immunohistochemical (IHC) assay intended for laboratory use for the qualitative detection of progesterone receptor (PR) antigen by light microscopy in sections of formalin fixed, paraffin embedded normal and neoplastic tissues on a Lab Vision automated slide stainer.

2. Indication(s) for use:

It is indicated as an aid in assessing the likelihood of response to therapy as well as in the prognosis and management of breast cancer patients

3. Special conditions for use statement(s):

N/A

4. Special instrument requirements:

Lab Vision Autostainer

I. Device Description:

The NeoMarkers Rabbit Monoclonal Anti-Human Progesterone Receptor (PR) (Clone SP2) Antibody is a semiquantitative immunohistochemical assay to identify PR expression in normal and neoplastic tissues routinely processed and paraffin-embedded. The antibodies are available as ready-to-use and concentrated and are optimized for use on the Lab Vision Autostainer.

NeoMarkers Rabbit Monoclonal Anti-Human PR Antibody (Ready-to-use) contains rabbit anti-human monoclonal antibody prediluted in 0.05 mol/L Tris-HCL, pH 7.6 containing stabilizing protein and 0.015 mol/L sodium azide. The specific antibody concentration is approximately 1.6 µg/mL.

NeoMarkers Rabbit Monoclonal Anti-Human PR Antibody (Concentrate) contains 1 mL (or 0.1 mL, 0.5 mL) concentrated tissue culture supernatant containing rabbit anti-human monoclonal antibody directed against PR antigen, with 0.05% sodium azide as a preservative. The specific antibody concentration is approximately 160 µg/mL.

2

{2}

3

J. Substantial Equivalence Information:

1. Predicate device name(s):
Ventana Anti-Progesterone Receptor (1A6) Primary Antibody

2. Predicate 510(k) number(s):
k990618

3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Antibody type | Monoclonal | Monoclonal |
| Intended use | Semi-quantitative
detection of PR | Semi-quantitative
detection of PR |
| Technology | Immunohistochemistry | Immunohistochemistry |
| Tissue Type | Formalin-fixed, paraffin
embedded breast tissue | Formalin-fixed, paraffin
embedded breast tissue |
| Differences | | |
| Item | Device | Predicate |
| Antibody origin | Rabbit | Mouse |
| Clone (PR) | SP2 | 1A6 |

K. Standard/Guidance Document Referenced (if applicable):
“Guidance for Industry: Guidance for Submission of Immunohistochemistry Applications to the FDA”

L. Test Principle:
NeoMarkers Rabbit Monoclonal Anti-Human PR Antibody, specifically binds to progesterone receptor antigen located in the nuclear region of a variety of normal and neoplastic tissues. Immunohistochemical staining is performed on routinely processed, paraffin-embedded specimens. Immunohistochemistry is a well established, widely accepted laboratory methodology. The specific antibody is localized by a biotin conjugated secondary antibody formulation that recognizes rabbit immunoglobulins. This step is followed by the addition of an avidin/streptavidin enzyme conjugate that binds to the biotin present on the secondary antibody. The specific antibody-secondary antibody-avidin/streptavidin enzyme

{3}

complex is then visualized with a precipitating enzyme reaction product, which is readily detected by light microscopy.

## M. Performance Characteristics (if/when applicable):

### 1. Analytical performance:

#### a. Precision/Reproducibility:

##### Intra-run Reproducibility

Ten serial sections were cut from each of three breast carcinoma blocks for a total of 30 slides. The slides were stained on the autostainer and staining intensity was evaluated. Each slide showed acceptable reproducibility to others in the test and there was no variation in staining intensity.

##### Inter-run Reproducibility

Ten serial sections were cut from each of three breast carcinoma blocks for a total of 30 slides. One slide from each block was stained on the autostainer for each of 10 days. Each slide showed acceptable reproducibility over the 10 days. One block showed greater than one degree of staining intensity variation on one day. The other slides showed no variation in staining intensity.

##### Inter-method Reproducibility

Ten different breast carcinoma blocks of varying positivity were stained using the manual method and the automated stainer to determine reproducibility between the different methods. There was acceptable reproducibility between the two methods.

#### b. Linearity/assay reportable range:

N/A

#### c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Positive and negative controls should be performed with each staining run. The pathologist is responsible for assuring that the assay is performing properly.

#### d. Detection limit:

N/A

{4}

e. Analytical specificity:

A total of 90 formalin-fixed and paraffin-embedded tissues covering a wide range of normal human tissue types were tested with the PR antibody. The antibody demonstrated negative immunoreactivity with most tissues. Positive immunoreactivity was noted with some normal tissues which are typically positive, like uterus, ovary and ductal epithelial cells of the breast.

f. Assay cut-off:

A positive staining result is defined as more than 10% of tumor cells with stained nuclei of any intensity.

2. Comparison studies:

a. Method comparison with predicate device:

Comparison of the Neomarkers PR antibodies was performed with the predicate device using breast carcinoma tissue arrays.

A total of 250 tissues were tested. There was 95.2% (238/250) total agreement (95% CI, 91.77-97.5%) between NeoMarkers PR antibody and the predicate device. The positive percent agreement was 98.83% (169/171) (95% CI, 95.84-99.86%). The negative percent agreement was 87.34% (69/79) (95% CI, 77.95-93.76%).

In addition, Cano et.al¹ investigated the PR status on 40 paraffin sections from breast cancer patients using the NeoMarkers PR antibody in comparison to the predicate device. Total agreement was observed: sensitivity was 100% (18/18), specificity was 100% (22/22), and accuracy was 100% (40/40).

¹ Cano, G. et.al. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn. Cytopathol. 29(4):207-211, 2003.

b. Matrix comparison:

N/A

3. Clinical studies:

a. Clinical Sensitivity:

N/A

{5}

b. Clinical specificity:
N/A

c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off:
N/A

5. Expected values/Reference range:
N/A

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

6